Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Cyanotech Corporation CYAN

Consumer Defensive — Packaged Foods

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
52.14%

Capital & Financial Ratios

Market Cap
1.65
Revenue
27.23
Net Income
(0.07)
Free Cash Flow
0.70
Net Debt
7.06
Current Ratio
1.06
Debt/Equity
1.02
P/E ratio
0.00
P/S ratio
0.12
P/B ratio
0.42
Past 5Y EPS Growth
—
This Y EPS Growth
—
Next Y EPS Growth
—
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 0.71 0.26 0.81 1.09
Receivables 2.10 1.95 3.25 2.23
Inventory 7.31 7.79 6.34 6.99
Other — — — —
10.59 10.55 10.87 10.94
2024 2025 2026 Q'26
Payables 1.44 2.22 1.70 1.25
ST’ Debt 4.39 5.89 7.24 7.16
Other 0.20 0.11 0.08 0.08
8.55 10.24 10.70 10.28
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jun Sep Dec Mar Year
’26 6.47 — — —
—
’26 5.82 6.98 5.88 7.91
26.59
’25 5.90 5.85 6.17 6.30
24.22
’24 5.15 6.37 5.58 5.97
23.07
’23 6.72 5.18 5.89 5.39
23.18
’22 8.96 9.42 9.46 8.13
35.97
’21 7.35 8.57 6.99 9.44
32.35
in millions of $

Operating Cash Flow

Jun Sep Dec Mar Year
’26 0.42 — — —
—
’26 (0.33) 0.11 (0.06) 0.52
0.23
’25 0.24 (0.44) (0.93) (0.06)
(1.19)
’24 (0.60) 0.83 (1.00) 0.31
(0.45)
’23 (1.30) (1.16) (0.22) 0.58
(2.10)
’22 (1.86) 2.28 0.92 1.04
2.38
’21 (0.15) 1.29 (0.22) 1.48
2.40
in millions of $

Free Cash Flow

Jun Sep Dec Mar Year
’26 0.36 — — —
—
’26 (0.35) 0.04 (0.06) 0.38
0.09
’25 0.20 (0.50) (0.99) (0.14)
(1.44)
’24 (0.75) 0.70 (1.04) 0.25
(0.84)
’23 (1.67) (1.47) (0.55) 0.53
(3.17)
’22 (2.03) 1.93 0.69 0.51
1.11
’21 (0.28) 1.12 (0.51) 1.30
1.64
in millions of $

EPS

Jun Sep Dec Mar Year
’26 — — — —
—
’26 (0.13) 0.00 — —
(0.18)
’25 (0.17) (0.16) (0.03) (0.09)
(0.45)
’24 (0.22) (0.13) (0.16) (0.30)
(0.81)
’23 (0.08) (0.15) (0.10) (0.23)
(0.55)
’22 0.08 0.15 0.06 0.04
0.35
’21 0.02 0.03 0.13 (0.03)
0.15

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.90 0.61 0.12 0.21 0.23 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 3.62 1.70 0.96 0.57 0.55 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 95 86 77 83 83 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.38 0.27 0.30 0.29 0.32 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.97 23.18 23.07 24.22 26.59 — — —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.72% 31.32% 25.77% 28.40% 32.62% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.18 (3.42) (5.26) (3.19) (1.28) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.07% (14.76%) (22.80%) (13.19%) (4.80%) — — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.15 (3.44) (5.27) (3.20) (1.28) — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.98 2.14 2.07 1.90 1.90 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.84 3.71 3.53 3.42 3.64 — — —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.35 (0.55) (0.81) (0.45) (0.18) — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 (0.34) (0.07) (0.17) 0.03 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.21) (0.17) (0.06) (0.03) (0.02) — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.18 (0.51) (0.13) (0.20) 0.01 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.17 2.62 1.81 1.26 1.05 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.16 6.24 6.53 7.07 7.30 — — —
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.63 0.00 0.00 0.00 0.00 — — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.58 0.24 0.08 0.10 0.08 — — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.06 0.34 0.16 0.28 0.29 — — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.64 0.47 0.29 0.38 0.36 — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.73 (3.45) (7.87) (6.32) (123.28) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.38 (2.10) (0.45) (1.19) 0.23 — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.27) (1.07) (0.38) (0.25) (0.14) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.11 (3.17) (0.84) (1.44) 0.09 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.44 5.39 2.04 0.30 0.17 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.83 6.41 5.39 6.89 8.24 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.24 5.44 4.68 6.63 7.43 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.49 16.35 11.81 8.88 7.66 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.85% (11.14%) (19.21%) (13.18%) (5.62%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.41% (8.38%) (17.40%) (10.10%) (2.38%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.79% (19.20%) (37.41%) (30.95%) (15.50%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Cyanotech Corporation has faced a decade of financial turbulence, with revenues dropping from $33.8 million in 2015 to $23.1 million in 2023, and a significant decline in stock price from $10.85 to $0.96 over the same period. Despite these setbacks, projections for 2024 and 2025 suggest a potential revenue rebound, driven by strategic initiatives and market expansion. However, the company must address its erratic profitability, as evidenced by a plummeting EBT margin from 0.68% in 2015 to -22.8% in 2023, and a declining gross margin, which highlights rising production costs and pricing pressures.

Insider transactions reveal a surge in insider buying, with over 100,000 shares acquired by a director in recent months, signaling strong insider confidence in Cyanotech’s future. This optimism is echoed by analysts, who have set price targets at $5.00, suggesting substantial upside potential if the company can execute its strategic plans effectively. Key priorities include cost management, market expansion, operational efficiency, and transparent investor communication. While the path to recovery is fraught with challenges, these strategic efforts could position Cyanotech for a turnaround, offering significant value to shareholders if successfully implemented.

Read full commentary →

Cyanotech Corporation (CYAN) Latest News

News by impact score

Fine-tune

6 Apr

4 Business Wire, 8:00 AM
ZIVO Bioscience secures commercial-scale manufacturing agreement with Cyanotech Corporation for Zivolife™ algal biomass production. Cyanotech secures a major commercial-scale production contract, providing new revenue stream and strengthening position in algal products.

10 Nov

3 , 8:00 AM
Cyanotech Corporation reported its financial results for the second quarter of fiscal 2026, highlighting a decrease in revenue compared to the previous year. The company attributed this decline to various market challenges and increased competition. Despite the downturn, Cyanotech remains focused on its strategic initiatives aimed at improving operational efficiency and product offerings. Management expressed optimism about future growth opportunities and ongoing investments in research and development. Revenue decline indicates challenges that may moderately affect financial performance and market positioning.

6 Aug

3 , 8:00 AM
Cyanotech Corporation reported its financial results for the first quarter of fiscal 2026, highlighting key metrics such as revenue, net income, and operational developments. The company experienced fluctuations in sales and expenses, impacting overall profitability. Management provided insights into strategic initiatives and market conditions affecting performance, while also outlining future growth prospects and challenges. Financial results indicate moderate fluctuations that may influence performance but are balanced by strategic initiatives.

20 Jun

3 Business Wire, 12:00 PM
Cyanotech Corporation reported financial results for the fourth quarter and fiscal year 2025, showing a 5% increase in revenue to $24.2 million and a significant reduction in operating loss by nearly 45%. Gross profit improved to $6.9 million with a gross margin of 28.4%. Despite these gains, the company remains cautious due to economic uncertainties and potential new tariffs. The net loss for the year was $3.2 million, or $0.45 per share, an improvement from a net loss of $5.3 million in fiscal 2024. The fourth quarter also saw a revenue increase of 5.5% compared to the previous year. Cyanotech will host a broadcast on June 23, 2025, to discuss these results further. The financial improvements indicate a moderately noticeable influence on future performance, but economic uncertainties may limit overall impact.

11 Feb

3 , 8:00 AM
Cyanotech Corporation reported its financial results for the third quarter and the first nine months of fiscal 2025, highlighting revenue growth and operational achievements. The company emphasized its commitment to sustainability and innovation in its product offerings, which contributed to improved financial performance. Management provided insights into future strategies aimed at enhancing market presence and operational efficiency. Revenue growth and operational achievements indicate a moderately noticeable influence on financial performance and market positioning.

12 Nov

3 , 8:00 AM
Cyanotech Corporation reported financial results for the second quarter and first six months of fiscal 2025. The financial results may moderately influence key areas such as financial performance and competitive positioning.

7 Aug

3 Business Wire, 8:00 AM
Cyanotech Corporation reported a 15% increase in net sales for the first quarter of fiscal year 2025, driven by higher sales of Astaxanthin products. However, the company experienced a decline in gross profit due to low production levels. Cyanotech aims to secure financing to meet market demand and expand supply. The article highlights both positive and negative aspects of Cyanotech's financial performance, indicating a moderately noticeable influence on the company's future.

26 Jun

3 Business Wire, 8:00 AM
Cyanotech Corporation reports financial results for the fourth quarter and fiscal year 2024, with flat sales but a shift in product mix. The company focuses on meeting market demand and expanding product offerings. The financial results show a moderately noticeable influence on Cyanotech's future performance, with a focus on managing supply to meet market demand and expanding product offerings.

28 Mar

4 Business Wire, 6:05 AM
Nutrex-Hawaii introduces BioAstin Hawaiian Astaxanthin in sugar-free gummy format with 12mg per serving. Significant impact likely on future and performance due to major product innovation and market expansion.

29 Feb

4 Insider Monkey, 3:04 PM
Global marine biotechnology market is growing, with Cyanotech Corp (CYAN) highlighted for its flagship product BioAstin Hawaiian Astaxanthin. The article highlights Cyanotech Corp's leadership in marine biotechnology and its significant impact on the market.

13 Feb

3 Insider Monkey, 8:17 AM
Cyanotech Corporation reports lower sales in Q3 2024 due to price-sensitive market and higher manufacturing costs. Lower sales and higher costs may moderately impact financial performance and competitive positioning.

9 Feb

4 Simply Wall St., 5:25 AM
Cyanotech reported a US$0.16 loss per share in the third quarter of 2024, with revenue down 5.2% and net loss widening by 71% from the same period in 2023. The significant increase in net loss and widening loss per share is likely to have a major impact on Cyanotech's future performance and investor sentiment.

8 Feb

3 , 8:00 AM
Cyanotech Corporation reports lower sales and increased losses for the third quarter and first nine months of fiscal year 2024. The financial results are expected to moderately influence the company's financial performance and competitive positioning.

23 Dec

3 Simply Wall St., 7:59 AM
Cyanotech insider raised stake by 42% in previous year. Insider transactions may moderately influence Cyanotech's future.

8 Nov

3 Business Wire, 8:00 AM
Cyanotech Corporation reports financial results for the second quarter and first six months of fiscal year 2024. The financial results show a mix of positive and negative indicators, which may moderately influence the company's future performance.

25 Aug

4 GuruFocus.com, 1:03 PM
Cyanotech Corp faces potential underperformance due to declining financial strength, profitability, and growth metrics. Financial indicators suggest challenging road ahead for Cyanotech Corp.

11 Aug

3 Business Wire, 8:00 AM
Cyanotech Corporation reports financial results for the first quarter of fiscal 2024, showing a decrease in net sales and operating loss. The financial results may moderately influence key areas such as financial performance and market sentiment.

1 Aug

4 Business Wire, 8:00 AM
Cyanotech appoints Collette Kakuk as Chief Strategic and Commercial Officer to drive global growth in microalgae market. Appointment of new Chief Strategic and Commercial Officer expected to significantly impact company's strategic direction and market positioning.

29 Jun

4 Simply Wall St., 6:11 AM
Cyanotech reported a loss of US$0.55 per share for FY 2023, down from a profit of US$0.35 in FY 2022. The significant decrease in earnings and revenue is likely to have a major impact on Cyanotech's future performance and investor sentiment.

3 Thomson Reuters StreetEvents, 5:18 PM
Cyanotech Corporation reports decline in sales and financial performance for Q4 2023. The financial results show a moderately noticeable influence on Cyanotech Corporation's future performance.

27 Jun

3 Business Wire, 5:00 PM
Cyanotech Corporation reports financial results for the fourth quarter and fiscal year 2023, showing a decrease in net sales and a shift in consumer spending. The financial results may moderately influence key areas such as financial performance and competitive positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us